These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30166017)

  • 21. Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer.
    Komatsu T; Nakamura K; Kawase A
    J Thorac Oncol; 2017 Sep; 12(9):e143-e144. PubMed ID: 28838715
    [No Abstract]   [Full Text] [Related]  

  • 22. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
    Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
    Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.
    Swami U; Smith M; Zhang J
    J Thorac Oncol; 2018 Sep; 13(9):e183-e184. PubMed ID: 30166022
    [No Abstract]   [Full Text] [Related]  

  • 24. [Progress of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer].
    Guo C; Zhang J; Li S
    Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):524-533. PubMed ID: 35899452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis.
    Giaj Levra M; Cotté FE; Corre R; Calvet C; Gaudin AF; Penrod JR; Grumberg V; Jouaneton B; Jolivel R; Assié JB; Chouaïd C
    Lung Cancer; 2020 Feb; 140():99-106. PubMed ID: 31911324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.
    Osa A; Uenami T; Koyama S; Fujimoto K; Okuzaki D; Takimoto T; Hirata H; Yano Y; Yokota S; Kinehara Y; Naito Y; Otsuka T; Kanazu M; Kuroyama M; Hamaguchi M; Koba T; Futami Y; Ishijima M; Suga Y; Akazawa Y; Machiyama H; Iwahori K; Takamatsu H; Nagatomo I; Takeda Y; Kida H; Akbay EA; Hammerman PS; Wong KK; Dranoff G; Mori M; Kijima T; Kumanogoh A
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
    Cooper MR; Alrajhi AM; Durand CR
    Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab.
    Khunger M; Velcheti V
    J Thorac Oncol; 2017 Jul; 12(7):e96-e97. PubMed ID: 28629548
    [No Abstract]   [Full Text] [Related]  

  • 29. Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.
    Funazo T; Nomizo T; Kim YH
    J Thorac Oncol; 2017 Sep; 12(9):e140-e141. PubMed ID: 28838713
    [No Abstract]   [Full Text] [Related]  

  • 30. Prolonged Disease Control with Nivolumab in Metastatic Lung Adenocarcinoma During Immunotherapy Era.
    Sari M; Saip P
    J Coll Physicians Surg Pak; 2018 Nov; 28(11):891-892. PubMed ID: 30369388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer.
    Ratnayake G; Shanker M; Roberts K; Mason R; Hughes BGM; Lwin Z; Jain V; O'Byrne K; Lehman M; Chua B
    Asia Pac J Clin Oncol; 2020 Feb; 16(1):56-62. PubMed ID: 31721446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.
    Krefting F; Basara N; Schütte W; Späth-Schwalbe E; Alt J; Thiel S; Kimmich M; Fischer JR; Kurz S; Griesinger F; Christoph DC
    Oncol Res Treat; 2019; 42(5):243-255. PubMed ID: 30995666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.
    Wu YL; Lu S; Cheng Y; Zhou C; Wang J; Mok T; Zhang L; Tu HY; Wu L; Feng J; Zhang Y; Luft AV; Zhou J; Ma Z; Lu Y; Hu C; Shi Y; Baudelet C; Cai J; Chang J
    J Thorac Oncol; 2019 May; 14(5):867-875. PubMed ID: 30659987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab.
    Gokozan HN; Friedman JD; Schmaier AH; Downes KA; Farah LA; Reeves HM
    Clin Lung Cancer; 2019 Sep; 20(5):e560-e563. PubMed ID: 31311716
    [No Abstract]   [Full Text] [Related]  

  • 35. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.
    Fujita K; Kim YH; Kanai O; Yoshida H; Mio T; Hirai T
    Respir Med; 2019 Jan; 146():66-70. PubMed ID: 30665520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The changing face of cancer treatments.
    Keohane D; Fitzgerald GP
    BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30173128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nivolumab in non-small-cell lung cancer with EGFR mutation.
    Yoshida H; Kim YH; Ozasa H; Nagai H; Sakamori Y; Tsuji T; Nomizo T; Yasuda Y; Funazo T; Hirai T
    Ann Oncol; 2018 Mar; 29(3):777-778. PubMed ID: 29161357
    [No Abstract]   [Full Text] [Related]  

  • 38. Tumor pseudoprogression during nivolumab immunotherapy for lung cancer.
    Mayoral M; Castañer E; Gallardo X; Andreu M; Dalmau E; Garcia Y
    Radiologia (Engl Ed); 2019; 61(6):498-505. PubMed ID: 31300214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood Predictive Biomarkers for Patients With Non-small-cell Lung Cancer Associated With Clinical Response to Nivolumab.
    Agulló-Ortuño MT; Gómez-Martín Ó; Ponce S; Iglesias L; Ojeda L; Ferrer I; García-Ruiz I; Paz-Ares L; Pardo-Marqués V
    Clin Lung Cancer; 2020 Jan; 21(1):75-85. PubMed ID: 31562055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
    Kanazu M; Edahiro R; Krebe H; Nishida K; Ishijima M; Uenami T; Akazawa Y; Yano Y; Yamaguchi T; Mori M
    Thorac Cancer; 2018 Dec; 9(12):1782-1787. PubMed ID: 30328672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.